Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

India's Biological E. to make Providence Therapeutics' mRNA COVID-19 vaccine

06/01/2021 | 06:57am EDT
FILE PHOTO: A woman holds a medical syringe and a small bottle labelled

BENGALURU (Reuters) - India's Biological E. said on Tuesday it has entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company's mRNA COVID-19 vaccine in India.

Biological E., which also has a separate deal to produce about 600 million doses of Johnson & Johnson's COVID-19 shot annually, will run a clinical trial of Providence's vaccine in India and seek emergency use approval for it, the company said in a statement.

Providence will sell up to 30 million doses of its mRNA vaccine, PTX-COVID19-B, to Biological E., and will also provide the necessary technology transfer of the shot, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses.

Financial details of the transaction were not disclosed.

India has been struggling with a devastating second wave of the pandemic and has managed to fully vaccinate only about 3% of its population. On Monday, the Serum Institute of India said it will increase production of AstraZeneca's shot by nearly 40% in June, a step towards bridging the shortfall in the country.

"The mRNA platform has emerged as the front runner in delivering the first vaccines for emergency use to combat the COVID-19 pandemic," said Mahima Datla, Biological E.'s managing director.

Messenger ribonucleic acid (mRNA) vaccines prompt the body to make a protein that is part of the virus, triggering an immune response. U.S. companies Pfizer and Moderna use mRNA technology in their COVID-19 shots.

India's drug regulator has approved clinical trials of another mRNA vaccine developed by local firm Gennova Biopharmaceuticals, and the government has said it will fund the studies.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Shailesh Kuber)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 11.51% 386.51 Delayed Quote.269.97%
PFIZER, INC. 3.91% 45.68 Delayed Quote.24.10%
Latest news "Economy & Forex"
03:03aLondon Shares to Open Higher as Traders Eye Economic Data
DJ
03:01aSONY : posts Q1 profit jump on pandemic demand for devices and content
RE
03:01aEPAZZ HOLDINGS : ZenaPay Bitcoin Wallet Will Support Linking to Credit and Debit Cards to Make Using Bitcoin Easier for Everyday Transactions
DJ
03:00aSpain's La Liga agrees to sell 10% stake to CVC for $3.2 billion
RE
03:00aFrom goal posts to fishnets, German investor Windhorst hurries to clear billion-plus debt
RE
02:59aHonda lowers fy22 vehicle sales forecast to 4.85 mln from 5 mln previously due to chip shortage
RE
02:55aU.S. oil drops for 3rd day on concerns COVID-19 variant spread to cut demand
RE
02:55aTaylor Wimpey raises profit view as UK housing demand stays strong
RE
02:52aU.S. oil drops for 3rd day on concerns COVID-19 variant spread to cut demand
RE
02:51aByteDance rival Kuaishou to end services of short video app Zynn this month
RE
Latest news "Economy & Forex"